Healthcare entity

Brookings Institution

organization

All 1 tracked stories fall under one category: regulation. Active Pharmaceutical Ingredients (APIs) is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. The 8 average consequence score is above the beat benchmark of 5.9 in the same window.

Last mentioned: Jul 9, 2026

Entity pulse

Recent coverage · Brookings Institution

1 story
8 avg impact
0% positive
100% negative

Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 100 percentage points.

  • 100% negative

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about Brookings Institution

All 1 tracked stories fall under one category: regulation. Active Pharmaceutical Ingredients (APIs) is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. The 8 average consequence score is above the beat benchmark of 5.9 in the same window. Source depth averages 3 original sources per story, versus 3 across the same-window beat baseline. We currently track 1 Healthcare story that mention Brookings Institution, all published on March 19, 2026.

Stories tracked
1
Sources per story
3

Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 30 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering Brookings Institution. Shared-story counts are live from our verified record — not editorial picks.

Stories mentioning Brookings Institution 1

Health Policy Negative

US Lawmakers Sound Alarm Over China’s Growing Dominance in Pharma Supply Chain

A high-profile House Select Committee hearing has highlighted the United States' critical dependence on Chinese active pharmaceutical ingredients (APIs). Lawmakers warn that Beijing is applying its successful industrial playbook from rare earths and EVs to corner the global medicine market, with Chinese pharma revenue projected to hit $2.1 trillion by 2030.

3 sources

Brookings Institution is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.

See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.